In an era marked by remarkable advancements in medical diagnostics, the global minimal residual disease (MRD) testing market is poised for unprecedented growth. Projections suggest that by 2031, the ...

Europe’s minimal residual disease (MRD) testing market has witnessed remarkable growth, underscoring its pivotal role in healthcare diagnostics. Valued at $265.6 million in 2021, this market is poised ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas ... T cell products for ...

Purpose: This study aims to investigate the status of natural killer (NK) cells and the role of T-cell immunoreceptor with Ig and ITIM domains (TIGIT)-mediated regulation in diffuse large B-cell ...

There are two types of lymphoma: Hodgkin's lymphoma and non-Hodgkin's lymphoma ... There are two main types of lymphocytes, called B cells and T cells. But the kind involved in this type of ...

In addition, there are several trials currently examining the combination of bortezomib and histone deacetylase inhibitors (HDACi) or 5-azacitidine in the relapsed refractory T-cell lymphoma setting.